Sascha Basten

Natural disasters, conflicts, labour shortages, and other recent global disruptions have illustrated how fragile pharmaceutical supply chains can be. As a result, risk mitigation strategies are essential and having a secondary supplier in place for the manufacturing of life-saving medicines should no longer be a nice to have but an essential part of outsourcing strategy.

In this session, our expert panellists will explore dual sourcing and splitting molecule production, focusing on four key dimensions: risk management, regulatory compliance, operational execution, and business strategy. They will share practical insights on how pharma companies and CMOs can implement dual sourcing effectively without compromising compliance, cost, or speed-to-market.

Key benefits of dual sourcing to be discussed include:

• Increased capacity and flexibility: Ensuring manufacturing scalability to meet fluctuating global demand.
• Enhanced supply chain resilience: Mitigating the impact of regional disruptions, quality issues, or supplier shutdowns.
• Improved supplier negotiation and leverage: Fostering competitive pricing, service quality, and stronger partnerships.